InnovationWell Discusses Innovation in Life Science & Healthcare Research & Product Development
The InnovationWell Community of Practice InterAction Meeting "Innovation in Life Science & Healthcare Research & Product Development" will take place 16-19 October 2006, Bryn Mawr College, Philadelphia, USA.
Zeiningen, Switzerland (PRWEB) October 2, 2006 -- The InnovationWell Community of Practice InterAction Meeting "Innovation in Life Science & Healthcare Research & Product Development" will take place 16-19 October 2006, Bryn Mawr College, Philadelphia, USA. The program will concentrate on themes of relevance to FDA’s Critical Path initiative integrated into the ongoing InnovationWell program themes of innovation and knowledge management in life science and healthcare product development and safety.
Topics in Knowledge Management in Clinical and Translational Research, Decision Support for R&D, Metabolomics, Predictive Toxicology, Medicinal Chemistry and Biomarkers & Systems Biology approaches will be covered in four days of InterAction Meeting program sessions. In addition to morning presentations and panel discussions, workshops will run each afternoon expanding on topics and methods, with bbq, social activity and poster sessions running on campus during the evenings.
A Metabolomics in Discovery & Development Program includes presentations and workshops from Rick Beger (NCTR, FDA), Alvin Berger (Metabolon), Don Robertson (Pfizer), Gregory Banik (Bio-RAD), Teresa Garrett (Duke University), Susan Connor (Glaxo SmithKline), Greg Maguire (SIDMAP), Bruce Kristal (Cornell University), Stanley Young (NISS), Andrew Lane (JG Brown Cancer Center, U. Louisville), Oliver Fiehn (UC Davis Genome Center), and Eric Nemec (Leco Corporation). "The meeting program will bring together top experts in industry, government and academia to discuss recent progress and current challenges in the field of metabolomics aimed towards applications for personalised medicine, new diagnostics and enhancing drug safety. Case studies describing recent progress in approaches as well as highlighting certain pitfalls will be presented." said program chair George Harrigan of Monsanto.
The FDA has identified the development of new biomarkers as one of the key opportunities to increase efficiency, predictability, and productivity in drug development. However "Despite the technological advances, especially in genomics, developing and 'qualifying' candidate biomarkers to generate a true clinical utility is still not a straightforward process." said Zentam Tsuchihashi of BristolMyersSquibb. A session on the application of Biomarkers in Drug Development will explore new advances and challenges in this area and will include a keynote from Keith Elliston, CEO (Genstruct), with Zentam Tsuchihashi discussing Biomarker Roles in Tumor Immunotherapy, Darius Dziuda (CCSU) will cover the topic of Multivariate BioMarkers, Michael Jones (Novartis) will discuss Proteomics applications whereas Bernd Bonnekoh (Otto-von-Guericke University) and Ansgar J. Pommer (SkinSysTec) will provide perspectives for Multi Epitope Ligand Kartography (MELK) and skin disease applications.
Michael Liebman, executive director of the Windber Research Institute, will chair a program examining the application of Knowledge Management techniques to increase R&D productivity along Critical Paths in clinical and translational research and will be joined by Delia Y. Wolf (Harvard Medical School), Peter Gates (Johnson & Johnson PR&D), Jonathan Sheldon (InforSense), Duane Shugars (Concentia Digital), Jian Wang (Biofortis), and Jeff Spitzner (Rescentris). Liebman pipped "The industry is very focused on the collection, integration and curation of data, but has not yet begun to take on the important role of extracting knowledge from this information."
The program also includes a Decision Support for Research & Development program which will examine the application of knowledge and risk management, systems biology, analytics, and new technologies in improving productivity and decision making in R&D, clinical research and development, and drug discovery and development sessions on Structure-based Drug Design, Screening, and Medicinal Chemistry.
Douglas Connect (www.douglasconnect.com)
Douglas Connect specializes in solutions of relevance to pharmaceutical and life science research and development, drug discovery, life science product development and healthcare product safety, providing services, consulting and training in knowledge management, collaboration support, informatics and electronic support systems for research and development. Douglas Connect also runs the eCheminfo network (www.echeminfo.com) dedicated to innovation topics and practices in drug discovery chemistry and informatics, and InnovationWell, a community of practice for innovation and knowledge management in the life science product life cycle. Douglas Connect is based in Zeiningen, Switzerland.
###
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/SG9yci1Qcm9mLUluc2UtU3VtbS1JbnNlLVplcm8=
Trackbacks/Comments Received
Utilising Knowledge Management to increase R&D Productivity along Critical Paths
from The Ferryman on Oct 2, 2006
|
|
The FDA Critical Path to new Medical Products report (http://www.fda.gov/oc/initiatives/criticalpath/) recognised that improvements in knowledge management and transfer between research and development could provide critical productivity improvements and have significant impact on the successful development of new healthcare treatments. Translational research involving multi-directional knowledge flows between basic science and clinical research are hence a primary area for both future improvement and new approaches. Development and evaluation have not kept pace in recent years with advances in R&D technologies (e.g., genomics, microarrays, in silico) so as to enable better and earlier identification of novel targets, innovative therapies, safety risks, benefits or target sub-populations. It appears that new technology has been put into place in the R&D part of the pipeline without the ability to interpret and understand it in later decision-making.(continued...)
|
|
Decision Support for Research & Development
from The Ferryman on Oct 2, 2006
|
|
The data created during drug discovery and development and from clinical research programs is great in volume and complicated in diversity. Additionally, both biological systems and chemical interventions in them are complex, as are the human, medical, industry and regulatory environments in which programs are created and carried out. Hence gathering together and processing all relevant sources of knowledge at any time in which a decision needs to be made is by its nature very difficult.
Selection and visualisation of the most relevant data required for insights and decisions is a challenging area to which increasingly sophisticated analytics tools are being applied. Concept mapping, knowledge maps, natural language processing of unstructured information, semantic classification and ontologies, and sophisticated visualisation tools all offer approaches which can be helpful in this area. Nevertheless, many knowledge management issues remain challenging in both the management and availability of information and in the selection and use of processing tools. (continued...)
|
|
Electronic Lab Notebooks and Knowledge Management in R&D
from The Ferryman on Oct 2, 2006
|
|
Please join us in Bryn Mawr on Tuesday 17 October 2006 to discuss the emerging roles of Knowledge Management and Electronic Laboratory Notebook solutions in managing multidisciplinary research activities, innovation and collaboration. The Open Event will take place alongside our InnovationWell and eCheminfo Autumn InterAction Meetings.
Attendance at the Open Event & Knowledge Café involves no registration fee. However seated places are limited and will be restricted to a confirmed guest list of 100. Please send an RSVP with your name and organisation via email to innovationwell [at] douglasconnect.com
|
|
Biomarker Discovery & Applications in Drug Development
from The Ferryman on Oct 2, 2006
|
|
The FDA has identified the development of new biomarkers as one of the key opportunities to increase efficiency, predictability, and productivity in drug development. I provide below a description of the presentation, discussion and workshop activity for the session on Biomarker Discovery & Applications in Drug Development which will take place on Thursday 19th October ’06 at the InnovationWell meeting at Bryn Mawr.
The session on the application of biomarkers in drug development will explore new advances and challenges in this area and will include a keynote from Keith Elliston, CEO (Genstruct), with Zentam Tsuchihashi (BMS) discussing Biomarker Roles in Tumor Immunotherapy, Darius Dziuda (CCSU) will cover the topic of Multivariate BioMarkers, Michael Jones (Novartis) will discuss Proteomics applications whereas Bernd Bonnekoh (Otto-von-Guericke University) and Ansgar J. Pommer (SkinSysTec) will provide perspectives for Multi Epitope Ligand Kartography (MELK) and skin disease applications. This latter work is being published in Nature Biotechnlogy and is featured on its mid-October cover. (continued...)
|
|
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/SG9yci1Qcm9mLUluc2UtU3VtbS1JbnNlLVplcm8=
Bookmark -
Del.icio.us |
Digg |
Furl It |
Spurl |
RawSugar |
Simpy |
Shadows |
Blink It |
My Web
|
